ClinicalTrials.gg
CompletedNCT02262585Updated Oct 13, 2014

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

A Phase 1 interventional study of BIBR 277 tablet and BIBR 277 capsule in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
All
01

Study summary

Study to investigate the bioequivalence of BIBR 277 tablet (Mannitol based) vs. BIBR 277 capsule

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 20 and \<= 35 years
  2. Weight: > 17.6 and \< 26.4 (Weight (kg) / Height (m)2)
  3. Subjects judged by the investigator to be eligible as study subjects, with no findings after screening
  4. Subjects who volunteer to participate and are able to fully understand and agree with this study by written

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  3. Chronic or relevant acute infections
  4. History of hepatic disorder (e.g., biliary cirrhosis, cholestasis)
  5. History of serious renal disorder
  6. History of or present bilateral renal artery stenosis or lack of unilateral kidney accompanying arterial stenosis
  7. History of or present cerebrovascular disorder
  8. History of hyperkalemia
  9. History of to active ingredient (Telmisartan) or other angiotensin II receptor antagonists
  10. History of or present orthostatic hypotension or faint
  11. Surgery of gastrointestinal tract (except appendectomy)
  12. History of alcohol or drug abuse
  13. Participation to another trial with an drug within 4 months prior to the trial
  14. Whole blood donation more than 400 mL within 3 months prior to the trial
  15. Whole blood donation more than 100 mL within 1 month prior to the trial
  16. Donation of constituent of blood of more than 400 mL within 1 month prior to the trial
  17. Any medication which might influence the result of the trial within 10 days prior to the trial
  18. Excessive physical activities within 7 days prior to the trial
  19. Alcohol drinking within 3 days prior to the trial
  20. Inability to comply with restriction of protocol
  21. Other than above, those who are judged by the investigator to be inappropriate as the subjects of the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    BIBR 277 tablet

    (Mannitol based)

    Drug: BIBR 277 tablet

  • Active comparator
    BIBR 277 capsule

    Drug: BIBR 277 capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (maximum observed concentration of the Telmisartan in plasma)

    Time frame: up to 72 hours after drug administration

  2. AUC0-72hr (area under the concentration-time curve of the Telmisartan in plasma from zero time to 72hr

    Time frame: up to 72 hours after drug administration

Secondary outcomes

  1. Individual time courses of the Telmisartan plasma concentrations

    Time frame: up to 72 hours after drug administration

  2. tmax (time to reach Cmax)

    Time frame: up to 72 hours after drug administration

  3. t1/2 (terminal half-life of the Telmisartan in plasma)

    Time frame: up to 72 hours after drug administration

  4. AUC0-∞(area under the concentration-time curve of Telmisartan in plasma from zero time to infinity)

    Time frame: up to 72 hours after drug administration

  5. MRT0-∞ (total mean residence time of Telmisartan molecules in the body)

    Time frame: up to 72 hours after drug administration

  6. Number of subjects with adverse events

    Time frame: up to 72 hours after drug administration

  7. Number of subjects with clinically significant findings in vital signs

    blood pressure, pulse rate

    Time frame: up to 72 hours after drug administration

  8. Number of subjects with clinically significant findings in ECG

    Time frame: up to 72 hours after drug administration

  9. Number of subjects with clinically significant findings in laboratory tests

    Time frame: up to 72 hours after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002 and a primary completion of Aug 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2014
First posted
Oct 13, 2014
Start
Jul 2002
Primary completionActual
Aug 2002
Last update
Oct 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02262585
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
Jul 2002
Primary completion
Aug 2002
Last update
Oct 13, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion